WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

Seed

Veritas Aortic Solutions raises $12M seed for a transcatheter aortic root conduit

MedDevice Startups Staff · Jun 1 · 1 min read · Via MD+DI

Veritas Aortic Solutions closed $12M in seed financing, announced June 1, 2026. A group of medtech angel investors led. Cedars-Sinai Intellectual Property Company and inQB8's existing investors participated. The company spun out of inQB8 Medical Technologies as a standalone business in late 2025. Co-founder Arshad Quadri is executive chairman and chief medical officer, and co-founder J. Brent Ratz is CEO.

TVARC, the Transcatheter Valved Aortic Root Conduit, is a single permanent implant. It combines a bioprosthetic aortic valve, an ascending aortic graft and Chameleon Eye coronary perfusion ports, delivered through a transfemoral catheter. The target is disease of the aortic root and ascending aorta, including dissections and aneurysms, which today means open-heart surgery. The seed money funds development through first-in-human use. Twelve million dollars gets a valved conduit to a first patient. A Series A will have to come before any IDE.

Questions & Answers

How much did Veritas Aortic Solutions raise?

Veritas Aortic Solutions closed a $12M seed round, announced June 1, 2026, led by a group of medtech angel investors with Cedars-Sinai Intellectual Property Company and inQB8's existing investors participating.

What is the Veritas Aortic Solutions TVARC device?

TVARC is a transcatheter implant that combines a bioprosthetic aortic valve, an ascending aortic graft and coronary perfusion ports to treat aortic root and ascending aortic disease without open-heart surgery.

Where is Veritas Aortic Solutions based?

Veritas Aortic Solutions is based in Costa Mesa, California, and spun out of inQB8 Medical Technologies in late 2025.

← Back to Fundraising